|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.57 AUD | -2.80% |
|
+1.32% | -8.94% |
| Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
| Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Clinuvel Pharmaceuticals Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net income was AUD 30.6 million compared to AUD 20.88 million a year ago. Basic earnings per share from continuing operations was AUD 0.619 compared to AUD 0.423 a year ago.
Diluted earnings per share from continuing operations was AUD 0.591 compared to AUD 0.403 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.94% | 476M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
CLINUVEL PHARMACEUTICALS LIMITED 
